Company intelligence / Profile preview
Hotgen Biotech
- Ownership
- Private
- Employees
- ~1036
- Development stage
- Other
Overview
Hotgen Biotech has a broad commercial portfolio in in-vitro diagnostics with global regulatory approvals including CE IVDR and FDA EUA. Its COVID‑19 antigen self-test kits are widely distributed internationally. The company has entered the innovative drug space with SGC001 Injection in clinical trials for acute myocardial infarction and AA001 monoclonal antibody entering Phase 1 trials for Alzheimer's disease.
- Therapeutic areas
- NeurologyPsychiatryInfectious DiseasesOncologyCardiovascular
- Modalities
- AntibodyMonoclonal antibodyDiagnostic reagentSmall molecule (for diagnostics)Enzyme-linked immunoassay
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Hotgen Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hotgen Biotech.